株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺がんの診断・治療:世界市場

Diagnostics and Therapeutics for Lung Cancer: Global Markets

発行 BCC Research 商品コード 331406
出版日 ページ情報 英文 178 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
肺がんの診断・治療:世界市場 Diagnostics and Therapeutics for Lung Cancer: Global Markets
出版日: 2015年05月30日 ページ情報: 英文 178 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の肺がん市場は2013年の203億米ドルから2014年に219億米ドルへ拡大しました。同市場は2014年から2019年にかけて7.8%のCAGRで拡大し、2019年に318億米ドルに達すると予測されています。

当レポートでは、世界にいおける肺がん診断市場の現状と見通しについて調査し、世界市場の概要、世界市場動向の分析、診断手法別の分析、バイオマーカーとその肺がん治療へ果たす役割の詳細分析、市場ダイナミクスの評価、競合情勢、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場定義・世界のがん統計
  • がん診断・治療管理
  • 肺がんの概要・統計
  • 肺がんの種類・病期
  • 肺がん診断・治療管理
  • 肺がん関連の市場課題
  • 肺がん市場の戦略
  • 主要企業の市場シェア
  • 世界の肺がん市場
  • 規制
  • 政府支援プログラム
  • 次世代がん検査の商業化
  • がん検査の規制要件
  • 米国における医療費償還コード
  • 遺伝子特許および検査の商業化
  • コンパニオン検査開発の影響
  • 結論・戦略的見通し
  • 市場のアンメットニーズ
  • パイプライン分析

第4章 肺がん診断市場

  • 概要
  • 研究開発
  • 革新
  • 動向
  • 規制
  • 競合情勢
  • 組織学/細胞学
  • 免疫測定法
  • フローサイトメトリー
  • 迅速検査
  • 分子アッセイ
  • 組織アレイ
  • 循環腫瘍細胞
  • ファーマコダイアグノスティクス、分子
  • バイオマーカー
  • その他の診断方法

第5章 肺がん治療市場

  • 概要
  • 化学療法
  • 化学療法における異なる条件
  • 化学療法薬
  • リニアアクセラレーター放射線治療装置
  • 放射線治療装置は時代遅れとなるべきではない

第6章 競合情勢

第7章 企業プロファイル

第8章 特許分析

図表リスト

目次
Product Code: PHM174A

REPORT HIGHLIGHTS

The global market for lung cancer grew to $21.9 billion in 2014 from $20.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 7.8% from 2014 to 2019, totaling $31.8 billion in 2019.

This report provides:

  • An overview of the global markets for lung cancer diagnostics and therapeutics.
  • Analyses of global market trends, with data from 2013, 2014, and projections of CAGRs through 2019.
  • Coverage of diagnostics such as histology/cytology, immunoassays, flow cytometery, rapid tests, molecular assays, tissue arrays, and circulating tumor cells.
  • In-depth analysis of biomarkers and how they are playing a role in lung cancer treatment.
  • Evaluation of the market's dynamics, specifically growth drivers, inhibitors, and opportunities.
  • A look at the competitive landscape through profiles of major players in the industry.

SCOPE OF THE REPORT

The report will analyze the lung cancer market as per diagnostics and therapeutics, and will also focus on the regulations and government supported programs impacting this market. Regionally, the focus of study will be the markets of North America, Europe, Asia-Pacific and Rest of the World (ROW).

This report includes various lung cancer diagnostics tests like histology/cytology, immunoassays, flow cytometry, rapid tests, molecular assays, tissue arrays, circulating tumor cells, pharmacodiagnostics, and molecular biomarkers, etc. Lung cancer therapeutics include chemotherapy, radiotherapy and surgery.

ANALYST'S CREDENTIALS

Vijay Laxmi has more than 20 years of domain experience. In addition to business research and consulting, she has conducted corporate briefings for top companies in a wide range of market segments. She has worked with major market research firms and handled projects for various consultancies, and has authored market research studies in the healthcare domain.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY AND OBJECTIVES
  • TITLE DESCRIPTION
  • SCOPE OF THE REPORT
  • MARKET STRUCTURE
  • INTENDED AUDIENCE
  • RESEARCH METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SCOPE OF LUNG CANCER
  • LUNG CANCER EPIDEMIOLOGY TRENDS
  • CURRENT DIAGNOSTICS AND THERAPEUTIC TREATMENTS OF LUNG CANCER
  • UNMET MARKET NEEDS
  • RESEARCH AND DEVELOPMENT (R&D) TRENDS
  • PIPELINE ANALYSIS
  • SUMMARY TABLE: GLOBAL MARKET FOR LUNG CANCER, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR LUNG CANCER, 2013-2019 ($ MILLIONS)

CHAPTER 3 - MARKET OVERVIEW

  • MARKET DEFINITION AND GLOBAL CANCER STATISTICS
  • CANCER DIAGNOSIS AND THERAPY MANAGEMENT
  • LUNG CANCER OVERVIEW AND STATISTICS
  • TYPES AND STAGES OF LUNG CANCER
    • NON-SMALL CELL LUNG CANCER (NSCLC)
      • Staging of NSCLC
    • SMALL CELL LUNG CANCER (SCLC)
      • Staging of SCLC
  • LUNG CANCER DIAGNOSIS AND THERAPY MANAGEMENT
  • MARKET ISSUES RELATED TO LUNG CANCER
    • HIGH DRUG COST
    • DRUG APPROVAL TIMELINE
    • DRUG RESISTANCE TO CANCER DRUGS
    • NOT ENOUGH PATIENTS IN CLINICAL TRIALS
    • FEDERAL EXPENDITURE
      • FIGURE 1: CANCER RESEARCH FUNDING, 2012 (DOLLARS PER LIFE COST)
      • FIGURE 2: FEDERAL FUNDING BY CANCER SITE, 2012 ($ MILLIONS)
      • FIGURE 3: FIVE-YEAR SURVIVAL RATES BY YEAR OF DIAGNOSIS (%)
    • RECESSION IN THE GLOBAL ECONOMY
    • INNOVATIONS IN METHODS OF DIAGNOSTICS AND THERAPEUTICS OF LUNG CANCER
    • LUNG CANCER MARKET ANALYSIS
    • NICE LIMITS THE USE OF ROCHE'S TARCEVA IN LUNG CANCER
    • ELI LILLY'S ALMITA LOSES PATENT WAR IN THE U.K.
    • FOCUS IS ON INCREASING DIFFERENTIATION BETWEEN THE THREE MAIN NSCLC SUBTYPES
    • DRUG RESISTANCE TO THERAPIES
    • USE OF LOW-DOSE COMPUTED TOMOGRAPHY TO DETECT EARLY-STAGE LUNG CANCER
    • LUNG CANCER IN NON-SMOKERS
    • ASTRAZENECA'S MEDI4736, A VERY VIABLE DRUG FOR TREATING LUNG CANCER
  • LUNG CANCER MARKET STRATEGIES
  • MARKET SHARE OF KEY COMPANIES
    • FIGURE: 4 MARKET SHARE OF KEY COMPANIES IN THE LUNG CANCER DIAGNOSTICS MARKET, 2014 (%)
  • GLOBAL MARKET FOR LUNG CANCER
    • TABLE 1: GLOBAL MARKET FOR LUNG CANCER BY TYPE, THROUGH 2019 ($ MILLIONS)
  • REGULATIONS
    • UNITED STATES
      • FIGURE 5: DRUG DISCOVERY AND DEVELOPMENT TIMELINE
    • CANADA
    • EUROPE
      • Nationalized Procedure
      • Mutual Recognition Procedure (MRP)
        • FIGURE 6: MUTUAL RECOGNITION PROCEDURE
      • Decentralized Procedure
        • FIGURE 7: DECENTRALIZED PROCEDURE
      • Centralized Procedure
    • INDIA
      • FIGURE 8: DRUG APPROVAL PROCESS IN INDIA
    • CHINA
      • Step 1: Application for Approval of Clinical Study (Clinical Trial or Bio-Efficacy Study)
        • FIGURE 9: DRUG APPROVAL PROCESS IN CHINA
      • Step 2: Conducting Clinical Studies
        • FIGURE 10: PROCEDURE FOR CLINICAL STUDIES
      • Step 3: Final Approval for Drug Registration (After Clinical Studies)
        • FIGURE 11: FINAL APPROVAL FOR DRUG REGISTRATION
    • AFRICA
  • GOVERNMENT-SUPPORTED PROGRAMS
    • UNITED STATES
    • CANADA
    • EUROPE
    • INDIA
    • CHINA
    • AFRICA
  • COMMERCIALIZING NEXT-GENERATION CANCER TESTS
    • FIGURE 12: PENETRANCE BREAKDOWN OF NEXT-GENERATION SEQUENCING TESTS, 2013 (%)
    • CURRENT MARKET SCENARIO
  • REGULATORY REQUIREMENTS OF CANCER TESTS
  • REIMBURSEMENT CODING IN THE U.S.
    • ICD
  • GENE PATENTS AND TEST COMMERCIALIZATION
    • GENE PATENTING
      • FIGURE 13: BREAKDOWN OF GENETIC TESTS MARKET, 2013 (%)
    • MAJOR COMPANIES IN THE GENETICS SERVICES MARKET
  • IMPACT OF COMPANION TEST DEVELOPMENT
  • CONCLUSIONS AND STRATEGIC IMPLICATIONS
  • UNMET MARKET NEEDS
  • PIPELINE ANALYSIS

CHAPTER 4 - LUNG CANCER DIAGNOSTICS MARKET

  • OVERVIEW
    • TABLE 2: GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 3: GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY DIAGNOSTIC TEST, THROUGH 2019 ($ MILLIONS)
  • RESEARCH AND DEVELOPMENT
  • INNOVATIONS
  • TRENDS
  • REGULATIONS
  • COMPETITIVE LANDSCAPE
  • HISTOLOGY/CYTOLOGY
    • MARKET OVERVIEW
      • TABLE 4: GLOBAL MARKET FOR HISTOLOGY/CYTOLOGY BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • IMMUNOASSAYS
    • MARKET OVERVIEW
      • TABLE 5: GLOBAL MARKET FOR IMMUNOASSAYS BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • FLOW CYTOMETRY
    • MARKET OVERVIEW
      • TABLE 6: GLOBAL MARKET FOR FLOW CYTOMETRY BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • RAPID TESTS
    • MARKET OVERVIEW
      • TABLE 7: GLOBAL MARKET FOR RAPID TESTS BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
      • TABLE 8: LIST OF ALERE TEST PRODUCTS
  • MOLECULAR ASSAYS
    • MARKET OVERVIEW
      • TABLE 9: GLOBAL MARKET FOR MOLECULAR ASSAYS BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
      • TABLE 10: MYRIAD GENETICS TESTS
  • TISSUE ARRAYS
    • MARKET OVERVIEW
      • TABLE 11: GLOBAL MARKET FOR TISSUE ARRAYS BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • CIRCULATING TUMOR CELLS
    • MARKET OVERVIEW
      • TABLE 12: GLOBAL MARKET FOR CIRCULATING TUMOR CELLS BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • PHARMACODIAGNOSTICS, MOLECULAR
    • MARKET OVERVIEW
      • TABLE 13: GLOBAL MARKET FOR PHARMACODIAGNOSTICS, MOLECULAR BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • BIOMARKERS
    • MARKET OVERVIEW
      • TABLE 14: GLOBAL MARKET FOR BIOMARKERS BY REGION, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE
  • OTHER DIAGNOSTICS METHODS
    • DIGITAL PCR
      • Market Overview
      • Competitive Landscape
    • MASS SPECTROMETRY
      • Market Overview
      • Competitive Landscape
    • CHROMOSOME ANALYSIS
      • Market Overview
      • Competitive Landscape
    • NEXT-GENERATION SEQUENCING
      • Market Overview
      • Competitive Landscape
    • SAMPLE PREPARATION AND SYSTEM AUTOMATION
      • Market Overview
      • Competitive Landscape
    • ROLE OF IN VIVO CELLULAR AND MOLECULAR IMAGING
      • Market Overview
      • Competitive Landscape

CHAPTER 5 - LUNG CANCER THERAPEUTICS MARKET

  • OVERVIEW
    • TABLE 15: GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 16: GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY THERAPY TYPE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 14: PREVALENCE OF LUNG CANCER BY TYPE, 2014 (%)
  • CHEMOTHERAPY
    • TABLE 17: GLOBAL MARKET FOR LUNG CANCER CHEMOTHERAPY BY REGION, THROUGH 2019 ($ MILLIONS)
  • DIFFERENT CONDITIONS IN CHEMOTHERAPY
    • FIGURE 15: BREAKDOWN OF LUNG CANCER DIAGNOSIS BY STAGE, 2004-2010 (%)
    • Chemotherapy after Surgery
    • Chemotherapy and Radiotherapy
    • Chemotherapy for Locally Advanced NSCLC or Cancer that Has Spread
  • CHEMOTHERAPY DRUGS
    • LOW-COST DESTINATION FOR CHEMOTHERAPY
      • TABLE 18: COST COMPARISON OF LUNG CANCER TREATMENTS IN THE U.S. AND INDIA ($)
    • INCREASING NUMBER OF LUNG CANCER PATIENTS IN THE U.S.
      • FIGURE 16: NUMBER OF CANCER CASES IN THE U.S. BY TYPE, 2014 (NUMBER OF CASES)
    • RADIOTHERAPY
      • TABLE 19: RADIATION THERAPY AND COST IN THE U.S., 2014 ($)
  • LINEAR ACCELERATOR RADIOTHERAPY MACHINES
    • PROTON THERAPY
    • PARTICLE THERAPY
      • FIGURE 17: ADVANTAGES AND DISADVANTAGES OF PARTICLE THERAPY
  • RADIOTHERAPY MACHINES MUST NOT BE OUTDATED
    • RADIOTHERAPY TO INCREASE GLOBALLY
      • TABLE 20: GLOBAL MARKET FOR LUNG CANCER RADIOTHERAPY BY REGION, THROUGH 2019 ($ MILLIONS)
    • SURGERY
      • TABLE 21: GLOBAL MARKET FOR LUNG CANCER SURGERY BY REGION, THROUGH 2019 ($ MILLIONS)
    • TYPES OF SURGERY
      • FIGURE 18: GLOBAL MARKET SHARE FOR LUNG CANCER SURGERY BY TYPE, 2014 (%)
      • Thoracotomy
      • Robotic Surgery
      • Video-Assisted Thoracoscopic Surgery (VATS)
    • GEOGRAPHICAL ANALYSIS OF LUNG CANCER SURGERIES
      • The U.S.
      • Europe
        • The U.K
      • APAC

CHAPTER 6 - COMPETITIVE LANDSCAPE

  • FIGURE 19: TOP STRATEGIC ACTIVITIES OF KEY COMPANIES, 2011-NOVEMBER 2014 (NUMBER)
  • TABLE 22: PRODUCT LAUNCHES AND APPROVALS IN THE LUNG CANCER MARKET, 2011 TO 2014
  • TABLE 23: AGREEMENTS AND EXPANSIONS IN LUNG CANCER MARKET, 2011 TO 2014
  • TABLE 24: MERGERS AND ACQUISITIONS AND OTHER STRATEGIES IN THE LUNG CANCER MARKET, 2011 TO 2014

CHAPTER 7 - COMPANY PROFILES

  • ABBOTT LABORATORIES
    • TABLE 25: ABBOTT'S PRODUCT PORTFOLIO
    • TABLE 26: ABBOTT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • ACCURAY INC.
    • TABLE 27: ACCURAY'S PRODUCT PORTFOLIO
    • TABLE 28: ACCURAY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • AGILENT TECHNOLOGIES
    • TABLE 29: AGILENT'S PRODUCT PORTFOLIO
    • TABLE 30: AGILENT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • ARRAY BIOPHARMA
    • TABLE 31: ARRAY BIOPHARMA'S PRODUCT PORTFOLIO
    • TABLE 32: ARRAY BIOPHARMA'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • ASURAGEN, INC.
    • TABLE 33: ASURAGEN'S PRODUCT PORTFOLIO
    • TABLE 34: ASURAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • BECKMAN COULTER, INC.
    • TABLE 35: BECKMAN COULTERS PRODUCT PORTFOLIO
  • BECTON DICKINSON
    • TABLE 36: BECTON DICKINSON'S PRODUCT PORTFOLIO
    • TABLE 37: BECTON DICKINSON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • BIOMERIEUX
    • TABLE 38: BIOMERIEUX'S PRODUCT PORTFOLIO
    • TABLE 39: BIOMERIEUX'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • BIO-RAD LABORATORIES
    • TABLE 40: BIO-RAD'S PRODUCT PORTFOLIO
    • TABLE 41: BIO-RAD'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • BOEHRINGER INGELHEIM
    • TABLE 42: BOEHRINGER INGELHEIM'S PRODUCT PORTFOLIO
    • TABLE 43: BOEHRINGER INGELHEIM'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • BRUKER CORPORATION
    • TABLE 44: BRUKER'S PRODUCT PORTFOLIO
    • TABLE 45: BRUKER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • COVIDIEN PLC
    • TABLE 46: COVIDIEN'S PRODUCT PORTFOLIO
    • TABLE 47: COVIDIEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • DAKO DENMARK A/S
    • TABLE 48: DAKO'S PRODUCT PORTFOLIO
    • TABLE 49: DAKO'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • DANAHER CORPORATION
    • TABLE 50: DANAHER'S PRODUCT PORTFOLIO
  • ELI LILLY
    • TABLE 51: ELI LILLY'S PRODUCT PORTFOLIO
    • TABLE 52: ELI LILLY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • ETHICON ENDO-SURGERY INC.
    • TABLE 53: ETHICON'S PRODUCT PORTFOLIO
    • TABLE 54: ETHICON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • HOLOGIC
    • TABLE 55: HOLOGIC'S PRODUCT PORTFOLIO
    • TABLE 56: HOLOGIC'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • MERCK MILLIPORE
    • TABLE 57: MERCK MILLIPORE PRODUCT PORTFOLIO
    • TABLE 58: MERCK MILLIPORE RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • OLYMPUS CORP.
    • TABLE 59: OLYMPUS' PRODUCT PORTFOLIO
  • PFIZER
    • TABLE 60: PFIZER'S PRODUCT PORTFOLIO
    • TABLE 61: PFIZER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • QIAGEN
    • TABLE 62: QIAGEN'S PRODUCT PORTFOLIO
    • TABLE 63: QIAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • RAYBIOTECH
    • TABLE 64: RAYBIOTECH'S PRODUCT PORTFOLIO
    • TABLE 65: RAYBIOTECH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • ROCHE DIAGNOSTICS
    • TABLE 66: ROCHE DIAGNOSTICS' PRODUCT PORTFOLIO
    • TABLE 67: ROCHE DIAGNOSTICS' RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • SIEMENS HEALTHCARE
    • TABLE 68: SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO
    • TABLE 69: SIEMENS HEALTHCARE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • SIGMA ALDRICH
    • TABLE 70: SIGMA-ALDRICH'S PRODUCT PORTFOLIO
    • TABLE 71: SIGMA-ALDRICH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • THERMO FISHER SCIENTIFIC
    • TABLE 72: THERMO FISHER'S PRODUCT PORTFOLIO
    • TABLE 73: THERMO FISHER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • TRANSGENE SA
    • TABLE 74: TRANSGENE'S PRODUCT PORTFOLIO
    • TABLE 75: TRANSGENE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
  • TRINITY BIOTECH
    • TABLE 76: TRINITY'S PRODUCT PORTFOLIO

CHAPTER 8 - PATENT ANALYSIS

  • FIGURE 20: NUMBER OF PATENTS BY REGION, 2011 TO NOVEMBER 2014 (NUMBER)
  • LIST OF PATENTS
    • UNITED STATES
      • TABLE 77: U.S. PATENTS, 2011 TO NOVEMBER 2014
    • EUROPE
      • TABLE 78: EUROPE'S PATENTS, 2011 TO NOVEMBER 2014
    • JAPAN
      • TABLE 79: JAPAN'S PATENTS, 2010 TO NOVEMBER 2014

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR LUNG CANCER, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: GLOBAL MARKET FOR LUNG CANCER BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 2: GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 3: GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY DIAGNOSTIC TEST, THROUGH 2019 ($ MILLIONS)
    • TABLE 4: GLOBAL MARKET FOR HISTOLOGY/CYTOLOGY BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 5: GLOBAL MARKET FOR IMMUNOASSAYS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 6: GLOBAL MARKET FOR FLOW CYTOMETRY BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 7: GLOBAL MARKET FOR RAPID TESTS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 8: LIST OF ALERE TEST PRODUCTS
    • TABLE 9: GLOBAL MARKET FOR MOLECULAR ASSAYS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 10: MYRIAD GENETICS TESTS
    • TABLE 11: GLOBAL MARKET FOR TISSUE ARRAYS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 12: GLOBAL MARKET FOR CIRCULATING TUMOR CELLS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 13: GLOBAL MARKET FOR PHARMACODIAGNOSTICS, MOLECULAR BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 14: GLOBAL MARKET FOR BIOMARKERS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 15: GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 16: GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY THERAPY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 17: GLOBAL MARKET FOR LUNG CANCER CHEMOTHERAPY BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 18: COST COMPARISON OF LUNG CANCER TREATMENTS IN THE U.S. AND INDIA ($)
    • TABLE 19: RADIATION THERAPY AND COST IN THE U.S., 2014 ($)
    • TABLE 20: GLOBAL MARKET FOR LUNG CANCER RADIOTHERAPY BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 21: GLOBAL MARKET FOR LUNG CANCER SURGERY BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 22: PRODUCT LAUNCHES AND APPROVALS IN THE LUNG CANCER MARKET, 2011 TO 2014
    • TABLE 23: AGREEMENTS AND EXPANSIONS IN LUNG CANCER MARKET, 2011 TO 2014
    • TABLE 24: MERGERS AND ACQUISITIONS AND OTHER STRATEGIES IN THE LUNG CANCER MARKET, 2011 TO 2014
    • TABLE 25: ABBOTT'S PRODUCT PORTFOLIO
    • TABLE 26: ABBOTT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 27: ACCURAY'S PRODUCT PORTFOLIO
    • TABLE 28: ACCURAY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 29: AGILENT'S PRODUCT PORTFOLIO
    • TABLE 30: AGILENT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 31: ARRAY BIOPHARMA'S PRODUCT PORTFOLIO
    • TABLE 32: ARRAY BIOPHARMA'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 33: ASURAGEN'S PRODUCT PORTFOLIO
    • TABLE 34: ASURAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 35: BECKMAN COULTERS PRODUCT PORTFOLIO
    • TABLE 36: BECTON DICKINSON'S PRODUCT PORTFOLIO
    • TABLE 37: BECTON DICKINSON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 38: BIOMERIEUX'S PRODUCT PORTFOLIO
    • TABLE 39: BIOMERIEUX'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 40: BIO-RAD'S PRODUCT PORTFOLIO
    • TABLE 41: BIO-RAD'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 42: BOEHRINGER INGELHEIM'S PRODUCT PORTFOLIO
    • TABLE 43: BOEHRINGER INGELHEIM'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 44: BRUKER'S PRODUCT PORTFOLIO
    • TABLE 45: BRUKER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 46: COVIDIEN'S PRODUCT PORTFOLIO
    • TABLE 47: COVIDIEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 48: DAKO'S PRODUCT PORTFOLIO
    • TABLE 49: DAKO'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 50: DANAHER'S PRODUCT PORTFOLIO
    • TABLE 51: ELI LILLY'S PRODUCT PORTFOLIO
    • TABLE 52: ELI LILLY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 53: ETHICON'S PRODUCT PORTFOLIO
    • TABLE 54: ETHICON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 55: HOLOGIC'S PRODUCT PORTFOLIO
    • TABLE 56: HOLOGIC'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 57: MERCK MILLIPORE PRODUCT PORTFOLIO
    • TABLE 58: MERCK MILLIPORE RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 59: OLYMPUS' PRODUCT PORTFOLIO
    • TABLE 60: PFIZER'S PRODUCT PORTFOLIO
    • TABLE 61: PFIZER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 62: QIAGEN'S PRODUCT PORTFOLIO
    • TABLE 63: QIAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 64: RAYBIOTECH'S PRODUCT PORTFOLIO
    • TABLE 65: RAYBIOTECH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 66: ROCHE DIAGNOSTICS' PRODUCT PORTFOLIO
    • TABLE 67: ROCHE DIAGNOSTICS' RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 68: SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO
    • TABLE 69: SIEMENS HEALTHCARE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 70: SIGMA-ALDRICH'S PRODUCT PORTFOLIO
    • TABLE 71: SIGMA-ALDRICH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 72: THERMO FISHER'S PRODUCT PORTFOLIO
    • TABLE 73: THERMO FISHER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 74: TRANSGENE'S PRODUCT PORTFOLIO
    • TABLE 75: TRANSGENE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014
    • TABLE 76: TRINITY'S PRODUCT PORTFOLIO
    • TABLE 77: U.S. PATENTS, 2011 TO NOVEMBER 2014
    • TABLE 78: EUROPE'S PATENTS, 2011 TO NOVEMBER 2014
    • TABLE 79: JAPAN'S PATENTS, 2010 TO NOVEMBER 2014

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR LUNG CANCER, 2013-2019 ($ MILLIONS)
    • FIGURE 1: CANCER RESEARCH FUNDING, 2012 (DOLLARS PER LIFE COST)
    • FIGURE 2: FEDERAL FUNDING BY CANCER SITE, 2012 ($ MILLIONS)
    • FIGURE 3: FIVE-YEAR SURVIVAL RATES BY YEAR OF DIAGNOSIS (%)
    • FIGURE 4: MARKET SHARE OF KEY COMPANIES IN THE LUNG CANCER DIAGNOSTICS MARKET, 2014 (%)
    • FIGURE 5: DRUG DISCOVERY AND DEVELOPMENT TIMELINE
    • FIGURE 6: MUTUAL RECOGNITION PROCEDURE
    • FIGURE 7: DECENTRALIZED PROCEDURE
    • FIGURE 8: DRUG APPROVAL PROCESS IN INDIA
    • FIGURE 9: DRUG APPROVAL PROCESS IN CHINA
    • FIGURE 10: PROCEDURE FOR CLINICAL STUDIES
    • FIGURE 11: FINAL APPROVAL FOR DRUG REGISTRATION
    • FIGURE 12: PENETRANCE BREAKDOWN OF NEXT-GENERATION SEQUENCING TESTS, 2013 (%)
    • FIGURE 13: BREAKDOWN OF GENETIC TESTS MARKET, 2013 (%)
    • FIGURE 14: PREVALENCE OF LUNG CANCER BY TYPE, 2014 (%)
    • FIGURE 15: BREAKDOWN OF LUNG CANCER DIAGNOSIS BY STAGE, 2004-2010 (%)
    • FIGURE 16: NUMBER OF CANCER CASES IN THE U.S. BY TYPE, 2014 (NUMBER OF CASES)
    • FIGURE 17: ADVANTAGES AND DISADVANTAGES OF PARTICLE THERAPY
    • FIGURE 18: GLOBAL MARKET SHARE FOR LUNG CANCER SURGERY BY TYPE, 2014 (%)
    • FIGURE 19: TOP STRATEGIC ACTIVITIES OF KEY COMPANIES, 2011-NOVEMBER 2014 (NUMBER)
    • FIGURE 20: NUMBER OF PATENTS BY REGION, 2011 TO NOVEMBER 2014 (NUMBER)
Back to Top